● Live Wisconsin AG suit vs Kalshi & Polymarket pending · NY/IL insider-trading orders in effect · Updated May 2026
← News & Updates
Regulation

CFTC Orders Kalshi to Halt 'Trump Mention' Markets — the Agency Restrains Its Own Protégé

The CFTC notified Kalshi that its 'mention' markets — contracts on what President Trump will say — are under a formal stay, forcing an indefinite pause pending a review of whether the contracts are 'readily susceptible to manipulation.' Kalshi has until December 11 to defend the products, and its CEO reportedly disagrees with the suspension. The action is notable because the CFTC has spent 2026 defending Kalshi against state enforcement; here the same agency is restricting one of Kalshi's own product lines.

The CFTC notified Kalshi that its 'mention' markets — contracts on what President Trump will say, such as whether he will use particular words in a speech — are subject to a formal stay, forcing an indefinite pause pending review. The CFTC is examining whether the contracts are 'readily susceptible to manipulation,' the statutory standard that lets the agency prohibit an event contract. Kalshi has until approximately December 11 to defend the products, and its CEO reportedly disagrees with the suspension. Mention markets have been among Kalshi's more contested categories: they were explicitly excluded from the company's proposed margin programme and from the CFTC's October move to classify event contracts as swaps, reflecting that contracts on speech content occupy a different and more problematic category than economic or financial contracts.

The manipulation concern is concrete and structural. A contract on whether a public figure will say a specific word can be influenced directly by that figure or by anyone with advance knowledge of a prepared speech. If a speechwriter, aide, or the speaker himself knows the content before delivery, they hold material non-public information that moves the contract with certainty — and in the most direct case, the subject can simply choose to say or not say the word, determining the outcome at will. This is a manipulability that does not exist in contracts on exogenous events like economic data or elections, where no single participant controls the outcome. The 'readily susceptible to manipulation' standard exists precisely for contracts of this kind, and the CFTC's review will assess whether mention markets can satisfy it.

For UK readers, the more significant feature is what the action reveals about the CFTC's dual role. Throughout 2026 the CFTC has been the sector's principal federal defender — suing more than a dozen states, asserting exclusive jurisdiction, moving to classify event contracts as swaps, and directing the platforms to stop geofencing. That record led Louisiana's attorney general to call the agency an 'obsequious standard bearer' for the platforms. The stay on Kalshi's mention markets complicates that: here the CFTC is exercising its authority against Kalshi, restricting a product the company wants to offer, on the same manipulation grounds state regulators and the NFL have raised generally. It demonstrates that defending the platforms' jurisdiction is not the same as approving every contract they list, and gives the CFTC a concrete rebuttal to the accusation that it is captured by the industry it regulates.

For Kalshi, the stay is a reminder that federal regulation carries obligations as well as protections. The company's legal strategy rests on the argument that CFTC oversight is adequate and preferable to state gambling regulation — an argument strongest when the CFTC is visibly exercising genuine oversight, which the stay demonstrates, but which also means Kalshi must accept the agency's authority to restrict its products, including popular ones. Mention markets on political figures' statements have been a distinctive, heavily-marketed Kalshi offering, and the indefinite pause removes a category that generated both volume and attention. The December 11 deadline sits alongside the other December milestones converging on the sector: the CFTC's geofencing compliance deadline around December 5, Kalshi's Supreme Court response brief due December 7, and the Louisiana preliminary injunction hearing on November 30. The mention-markets review adds the question of which specific contracts the CFTC will actually permit to the larger question of whether the platforms can operate at all.

Operators mentioned in this article


Recent updates


Fourth Circuit Rules Against Kalshi in Maryland — Circuit Split Widens to 3-1 With a Notable Dissent

A divided Fourth Circuit panel ruled 2-1 on November 17 that Maryland gaming regulators can pursue enforcement against Kalshi over unlicensed sports betting, rejecting the platform's CFTC-preemption argument. Judge DeAndrea Benjamin dissented, arguing that Kalshi's sports event contracts are 'swaps' under exclusive CFTC oversight — the first appellate dissent on the pro-Kalshi side. The ruling makes the Fourth Circuit the third appeals court to rule against Kalshi, deepening the split to three circuits against (Fourth, Sixth, Ninth) and one for (Third), with the Supreme Court cert petition pending.

CFTC and DOJ Sue Louisiana and Arkansas as Federal-State Fight Turns Openly Hostile

Louisiana Attorney General Liz Murrill won a temporary restraining order on November 12 against 31 prediction market entities, including Kalshi, Polymarket, Robinhood, and Coinbase, with a preliminary injunction hearing set for November 30. The CFTC — now joined by the Department of Justice — sued both Louisiana and Arkansas to block the state enforcement, marking Louisiana as the twelfth state the agency has taken to court. The dispute has turned personal: Murrill called CFTC Chairman Michael Selig an 'obsequious standard bearer' for the platforms, while Selig characterised her lawsuit as 'naked lawfare.' The DOJ's involvement escalates the federal response beyond the CFTC acting alone.

Kalshi and Polymarket Expand Into Health Contracts — Measles, Drug Trials, FDA Approvals Draw Scrutiny

Kalshi and Polymarket have added event contracts tied to US public health outcomes, including measles case-count thresholds settled using CDC data, clinical drug-trial results, and FDA regulatory approvals. Two Democratic senators wrote to the Department of Health and Human Services on November 11 raising concerns about the drug-trial and FDA markets, particularly the risk that people with confidential access to trial data or agency decisions could profit from disclosing it. Kalshi says it has implemented guardrails, such as limiting markets to late-stage trials. The expansion extends the debate over whether some prediction market categories commodify sensitive public outcomes in harmful ways.